| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies | Company's Home Page |
| Sequenom Industrial Genomics, Inc. |
| 11555 Sorrento Valley Road, San Diego, CA * (921) 21-2121 |
| Business Description | The company is a pioneer in the new field of industrial genomics. Industrial genomics is the large scale commercial use of the knowledge of DNA variations for improving health, agriculture and livestock. |
| Offering Information Company has | |||
| Trading As | SQNM (NASNTL) | Industry | Service (SIC 8731) |
| Type of Stock Offered | Common Shares | Filing Date | 11/24/99 |
| Domestic Shares Offered | 5,000,000 | Offer Date | 1/31/00 |
| Foreign Shares Offered | 0 | Filing Range | $16.00 - $18.00 |
| Company Shares | 5,000,000 | Offer Price | $26.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $1.820 |
| Gross Proceeds | $130,000,000 | Selling | $1.100 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | - - | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Warburg Dillon Read LLC | Lead Manager | (203) 719-3000 |
| Robertson, Stephens & Company | Co-manager | (415) 989-8500 |
| SG Cowen | Co-manager | (212) 495-6000 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 9 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/97 | 12/31/98 | 9/30/98 | 9/30/99 | |||
| Revenues | - | - | - | - | - | - | - |
| Income from Oper. | - | - | - | -4.866 | -10.055 | -6.064 | -16.035 |
| Net Income | - | - | - | -5.117 | -10.271 | -6.003 | -15.386 |
| E.P.S | - | - | - | -22.620 | -33.330 | -20.120 | -39.410 |
| Revenue Growth (%) | - | - | - | - | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -7.79 | -5.47 | -9.49 | ||||
| Cash Flow - Inv. | -23.75 | -2.61 | -8.45 | ||||
| Cash Flow - Fin. | 39.16 | 14.19 | 12.49 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 9/30/99 | Financial Ratios | ||||
| Total Assets | 34.63 | Current Assets | 28.75 | Current Ratio | 7.23 |
| Total Liab. | 11.66 | Current Liab. | 3.98 | Debt Ratio | 33.68% |
| Total Equity | 22.97 | Working Cap. | 24.77 | Debt to Equity Ratio | 0.51 |
| Cash | 3.05 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for general corporate purposes, including hiring additional sales and customer support personnel, expansion of our facilities, continued development and manufacturing of existing products, research and development of additional products, patent prosecution expenses, working capital and potential acquisitions of products, technologies or companies and repayment of long-term debt and accrued interest. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Brobeck, Phleger & Harrison |
| Bank's Law Firm | Shearman & Sterling |
| Registrar/Transfer Agent | American Stock Transfer & Trust Co |
| Auditor | Ernst & Young |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |